Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity

Endocrinology

Volumn 153, Issue 7, 2012, Pages 2963-2973

  Xu, Mei ^a,c   Knox, Aaron J ^a,c   Michaelis, Katherine A ^a,c   Kiseljak Vassiliades, Katja ^a,c   Kleinschmidt DeMasters, Bette K ^b   Lillehei, Kevin O ^b   Wierman, Margaret E ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CLINICAL ARTICLE; COLONY FORMATION; DNA METHYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOBLOTTING; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; REPRIMO GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CPG ISLANDS; CYTOPLASM; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLYCOPROTEINS; HUMANS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PITUITARY GLAND; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 84862728850     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-2021     Document Type: Article

References (28)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101:613-619 (Pubitemid 38970613)
2. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603-1618 (Pubitemid 38063716)
3. Knox AJ, Xu, M., Wierman, ME Role of Reprimo in pituitary tumorigenesis. 11th International Pituitary Congress, Washington, DC, 2009
4. Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A 1990 Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336-340 (Pubitemid 20227010)
5. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws Jr ER 2002 The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96:195-208 (Pubitemid 34230231)
6. Ezzat S 2003 Pituitary tumor pathogenesis - the hunt for novel candidate genes continues. J Clin Endocrinol Metab 88:5116-5118 (Pubitemid 37452704)
7. Shorts-Cary L, Xu M, Ertel J, Kleinschmidt-Demasters BK, Lillehei K, Matsuoka I, Nielsen-Preiss S, Wierman ME 2007 Bone morphogenetic protein and retinoic acid-inducible neural specific protein-3 is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration, and invasion. Endocrinology 148:967-975
8. Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, Geraci M, Kleinschmidt-DeMasters BK, Lillehei KO, Wierman ME 2011 Identification of growth arrest and DNA-damage-inducible gene β (GADD45β) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 152:3603-3613
9. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A 2002 Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87:1262-1267 (Pubitemid 36121097)
10. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A 2003 A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88:5119-5126 (Pubitemid 37452705)
11. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, Taniguchi T 2000 Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 275:22627-22630 (Pubitemid 30646143)
12. Taylor WR, Stark GR 2001 Regulation of the G2/M transition by p53. Oncogene 20:1803-1815 (Pubitemid 32458690)
13. Wong TS, Kwong DL, Sham JS, Wei WI, Yuen AP 2005 Methylation status of Reprimo in head and neck carcinomas. Int J Cancer 117:697 (Pubitemid 41504562)
14. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba, II, Meltzer SJ, Gazdar AF 2005 Aberrant methylation of Reprimo in human malignancies. Int J Cancer 115:503-510 (Pubitemid 40656706)
15. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F 2004 A model-based background adjustment for oligonucleotide expresion arrays. J Am Stat Assoc 99:909-917 (Pubitemid 39665934)
16. Xu M, Shorts-Cary L, Knox AJ, Kleinsmidt-DeMasters B, Lillehei K, Wierman ME 2009 Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: role in proliferation and survival. Endocrinology 150:2064-2071
17. Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, Paun BC, Kan T, Cheng Y, Wang S, Yang J, Abraham JM, Meltzer SJ 2006 Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. Clin Cancer Res 12:6637-6642 (Pubitemid 44876831)
18. Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, Takahashi T, Gazdar AF, Frenkel EP 2006 Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 242:222-230 (Pubitemid 44485305)
19. Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart, II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D 2007 Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 3:89
20. Suzuki M, Shigematsu H, Takahashi T, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Gazdar AF 2005 Aberrant methylation of Reprimo in lung cancer. Lung Cancer 47:309-314 (Pubitemid 40248735)
21. Otsuka T, Kohno T, Mori M, Noguchi M, Hirohashi S, Yokota J 1996 Deletion mapping of chromosome 2 inhumanlung carcinoma. Genes Chromosomes Cancer 16:113-119 (Pubitemid 26239128)
22. Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S 2001 Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 30:113-122 (Pubitemid 32044592)
23. Olaru A, Mori Y, Yin J, Wang S, Kimos MC, Perry K, Xu Y, Sato F, Selaru FM, Deacu E, Sterian A, Shibata D, Abraham JM, Meltzer SJ 2003 Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors. Lab Invest 83:1867-1871 (Pubitemid 38018550)
24. Malik S, Jiang S, Garee JP, Verdin E, Lee AV, O'Malley BW, Zhang M, Belaguli NS, Oesterreich S 2010 Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol 30:399-412
25. Brooks CL, Gu W 2006 p53 ubiquitination: Mdm2 and beyond. Mol Cell 21:307-315 (Pubitemid 43163526)
26. Haupt Y, Maya R, Kazaz A, Oren M 1997 Mdm2 promotes the rapid degradation of p53. Nature 387:296-299 (Pubitemid 27220766)
27. Kubbutat MH, Jones SN, Vousden KH 1997 Regulation of p53 stability by Mdm2. Nature 387:299-303 (Pubitemid 27220767)
28. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y, Verhaegen M, Varambally S, Chinnaiyan AM, Jakubowiak AJ, Soengas MS 2007 Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104:19488-19493